Investigating how leukemia stem cells can be targeted for better treatment of acute myeloid leukemia.
Translational Control of Leukemia Stem Cells - Resubmission - 1
This study is looking at how certain genes affect leukemia stem cells in people with acute myeloid leukemia (AML) and is testing a new treatment that targets a specific marker called CD99 to help get rid of these harmful cells and improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10877816 on NIH RePORTER |
What this research studies
This research focuses on understanding the genetic factors that control leukemia stem cells (LSCs) in acute myeloid leukemia (AML), a condition with limited treatment options. The team has identified a specific antigen, CD99, which is present in a majority of AML cases and plays a crucial role in the growth and survival of these stem cells. By using novel monoclonal antibodies that target CD99, the researchers aim to eliminate LSCs, potentially leading to improved treatment outcomes for patients. The study involves isolating LSCs and assessing the effects of CD99 loss on these cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acute myeloid leukemia who have not responded well to existing treatments.
Not a fit: Patients with other types of leukemia or those who are not diagnosed with acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with acute myeloid leukemia by targeting the root cause of the disease.
How similar studies have performed: This approach is novel, as targeting CD99 in leukemia stem cells has not been extensively tested in previous research.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Park, Christopher Y — New York University School of Medicine
- Study coordinator: Park, Christopher Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.